External Collaborative Research (ECR)
External Collaborative Research (ECR) supports non-commercial sponsors conducting clinical, observational, and health outcomes studies to investigate disease progression, treatments, and patient experience.
Funder: Boehringer Ingelheim
Due Dates: Ongoing review (German clinical research funding process)
Funding Amounts: Drug and/or financial support may be provided
Summary: Supports non-commercial sponsors collaborating with Boehringer Ingelheim on clinical, observational, real-world evidence, and health outcomes research.
Key Information: The non-commercial sponsor retains sole regulatory and operational responsibility; Boehringer Ingelheim does not act as regulatory sponsor.
Description
Boehringer Ingelheim’s External Collaborative Research (ECR) program supports studies conducted under the sole responsibility of a non-commercial sponsor. Qualified academic and community-based scientists or consortia can propose research and collaborate with the company on protocol development, analysis, and publication. Eligible work includes pre- and post-marketing interventional trials, non-interventional studies such as observational and real-world evidence research, and non-commercial health economics and outcomes research.
Boehringer Ingelheim may contribute expertise on study objectives, design, protocols, data ownership, intellectual property, statistical analysis plans, reports, and publications, including co-authorship. These contributions are defined in an ECR Agreement. The sponsor retains final decision-making authority and responsibility for initiating, managing, financing, and operationalizing the study. Boehringer Ingelheim has no role in operational execution.
